Clinical Rheumatology最新文献

{"title":"TNF ınhibitor resistance in ankylosing spondylitis: is Helicobacter pylori the overlooked culprit?","authors":"Reyhan Bilici, Gizem Tuğçe Alp, Selma Özlem Çelikdelen, Mehmet Akif Öztürk, Murat Kekilli","doi":"10.1007/s10067-025-07536-3","DOIUrl":"10.1007/s10067-025-07536-3","url":null,"abstract":"<p><strong>Background: </strong>Ankylosing spondylitis (AS) is a chronic inflammatory disease that poses challenges in treatment due to resistance to anti-tumour necrosis factor (anti-TNF) therapies. This study investigates whether Helicobacter (H. pylori) infection contributes to reduced anti-TNF treatment response in AS patients.</p><p><strong>Methods: </strong>A cross-sectional study was conducted on 159 patients with AS. H. pylori infection was assessed using serological assays (ELISA for Iga and Igg), histopathological examination of gastric biopsies, and stool antigen testing. Disease activity and functional impairment were evaluated using ESR, CRP, BASFI, and ASDAS-CRP scores.</p><p><strong>Results: </strong>Patients with anti-TNF therapy resistance exhibited significantly higher H. pylori Iga seropositivity (p = 0.01) and histopathological positivity (p = 0.03). Additionally, they had longer anti-TNF treatment duration and higher inflammatory markers, including ESR, CRP, BASFI, and ASDAS-CRP scores, indicating a more significant inflammatory burden and functional impairment.</p><p><strong>Conclusion: </strong>Our findings suggest chronic H. pylori infection may contribute to anti-TNF therapy resistance in AS by promoting systemic inflammation and gut barrier dysfunction. These results underscore the importance of early, aggressive treatment strategies and suggest that H. pylori eradication may potentially enhance the efficacy of anti-TNF drugs. Future interventional studies are required to validate these findings and explore H. pylori screening as a therapeutic approach in AS management.</p><p><strong>Key points: </strong>• Resistance to anti-TNF therapy in AS presents a significant challenge, with the underlying mechanisms not yet fully understood. • This study identifies Helicobacter pylori (H. pylori) infection as a potential contributor to anti-TNF drug resistance in ankylosing spondylitis (AS), with Iga seropositivity and histopathological positivity being markedly higher in resistant patients. • Chronic H. pylori infection may promote systemic inflammation and gut barrier dysfunction, hindering immune responses to anti-TNF therapies. Patients exhibiting therapy resistance showed a more substantial inflammatory burden, including elevated ESR, CRP, BASFI, and ASDAS-CRP scores, which reinforces the connection between persistent inflammation and treatment failure. • Targeting H. pylori through screening and eradication could enhance the efficacy of anti-TNF drugs and improve treatment outcomes for patients with AS.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":"3201-3207"},"PeriodicalIF":2.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144324675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical value of metagenomic next-generation sequencing in patients with connective tissue diseases co-infections: a single-center study from southern hospital in China.","authors":"Yuan-Yuan Xiao, Ai-Ling Lu, Han-You Mo, Zhen-Dong He, Jia-Le Wen, Xuan Yin","doi":"10.1007/s10067-025-07525-6","DOIUrl":"10.1007/s10067-025-07525-6","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to assess the clinical value of metagenomic next-generation sequencing (mNGS) in patients with connective tissue diseases (CTDs) co-infections, thereby establishing a foundation for early infection identification and the development of anti-infective regimens.</p><p><strong>Methods: </strong>This retrospective study analyzed 304 CTD patients with suspected infections at the First Affiliated Hospital of Guangxi Medical University between October 2020 and April 2024. The study compared the diagnostic efficacy between mNGS and conventional microbiological testing (CMT), examined pathogen detection rates across different periods and pathogen types, and evaluated the clinical outcomes of mNGS-guided antimicrobial regimen adjustments.</p><p><strong>Results: </strong>Among the 180 confirmed infections (Group I), mNGS demonstrated superior diagnostic performance compared to conventional microbiological testing (CMT). mNGS exhibited significantly higher sensitivity (89.6% vs. 57.0%; OR = 6.5, 95% CI: 3.7-11.0, p < 0.001), with a specificity of 81.5%, positive predictive value (PPV) of 97.2%, and negative predictive value (NPV) of 52.4%. mNGS outperformed CMT in detecting bacterial and viral pathogens (p < 0.05). Viral infections were the most common. Compared to prior studies, mNGS exhibited improved pathogen detection rates. mNGS-guided treatment optimization significantly enhanced clinical outcomes, with higher cure rates, lower mortality, and shorter hospital stays.</p><p><strong>Conclusion: </strong>Current evidence suggests that while mNGS demonstrates superior diagnostic performance over CMT for detecting infections in CTD patients, their combined use provides optimal pathogen identification accuracy and enhanced clinical management. Key Points • This is the larger-scale retrospective study of mNGS application in patients with CTDs co-infections following the Coronavirus Disease 2019 (COVID-19). • We found that the distribution of pathogens and positivity rates have changed in recent years, especially after the COVID-19. • The clinical value of mNGS was further demonstrated through its impact of mNGS results on antibiotic regimens and the analysis of negative samples.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":"3265-3275"},"PeriodicalIF":2.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144332567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medication effects on uric acid levels in rheumatoid arthritis studies.","authors":"Amir Reza Akbari, Benyamin Alam","doi":"10.1007/s10067-025-07538-1","DOIUrl":"10.1007/s10067-025-07538-1","url":null,"abstract":"","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":"3379"},"PeriodicalIF":2.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144332569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rebuttal for letter to the editor from Miss Nassar and Dr Thombs regarding: \"A systematic review of prevalence and predictors of depression in systemic sclerosis based on the CES-D, BDI, and PHQ-9 self-assessment questionnaires\".","authors":"Esra Mehmetoglu, Anvitha Mummadisetty, Andreas Chatzittofis, Konstantinos Parperis, Nora Sandorfi, Chris T Derk","doi":"10.1007/s10067-025-07555-0","DOIUrl":"10.1007/s10067-025-07555-0","url":null,"abstract":"","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":"3387"},"PeriodicalIF":2.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The clinical features and mortality predictors for idiopathic inflammatory myopathies: a retrospective study of 572 patients and the \"AIRMT\" Score.","authors":"Youchao Yu, Yinfang Liu, Xuemei Zhu, Yingmeng Ni, Ranran Dai, Hua Cao, Guochao Shi, Yun Feng","doi":"10.1007/s10067-025-07495-9","DOIUrl":"10.1007/s10067-025-07495-9","url":null,"abstract":"<p><strong>Introduction/objectives: </strong>Idiopathic inflammatory myopathies (IIM) accompanied with interstitial lung disease (ILD) are often rapidly progressive and associated with poor prognosis. This study aims to explore the different clinical characteristics and prognostic factors for IIM with and without ILD and to develop a simple predictive model.</p><p><strong>Methods: </strong>We retrospectively evaluated 572 consecutive patients with IIM from January 2017 to May 2022. Clinical characteristics, comorbidities, survival outcomes, and treatments were assessed. The predictors of all-cause mortality were investigated by Cox regression analysis. An ROC curve was drawn to evaluate the predictive value of independent risk factors.</p><p><strong>Results: </strong>Patients with IIM-ILD were older and exhibited more respiratory and arthritis symptoms, but fewer tumor comorbidities. The first-year survival rate was 86% for ILD and 95% for non-ILD. The mortality rate in IIM-ILD patients was higher than in non-ILD patients (15.9% vs 6.2%, P = 0.001). ILD patients were more susceptible to various types of infections (bacteria, Pneumocystis jirovecii pneumonia (PJP), fungi, cytomegalovirus, all P < 0.001) and had a higher incidence of intubation (5.1% vs 1.2%, P = 0.009). Age, respiratory failure (RF), tumor, and MDA5 antibodies were independent predictors of survival for both IIM and IIM-ILD. Then, we established the \"AIRMT\" score and simple \"AIRMT\" score, which demonstrated good predictive capabilities with an AUC of 0.816 (95% CI 0.766-0.866) and 0.791 (95% CI 0.737-0.846).</p><p><strong>Conclusions: </strong>IIM-ILD patients have higher mortality rates and are more susceptible to infections than non-ILD. This study identified various clinical features and several risk factors associated with all-cause mortality in IIM. The \"AIRMT\" score was constructed as a reliable survival predictor, offering valuable guidance for further research. Key Points • Patients with IIM-ILD were older and exhibited more respiratory and arthritis symptoms but had fewer tumor comorbidities. • IIM-ILDs have higher all-cause mortality rates and are more prone to infections compared to non-ILD cases. • Age, respiratory failure, tumor comorbidity, and MDA5 antibodies are identified as independent predictors of survival for both IIM and IIM-ILD patients. • We developed a practical clinical model, the \"AIRMT\" score, which could be a reliable and easy-to-evaluate clinical tool to predict all-cause mortality.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":"3253-3264"},"PeriodicalIF":2.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying common genes and immune infiltration characteristics between systemic sclerosis and atherosclerosis.","authors":"Yanqing Pan, Binbing Shi, Fangnan Zang, Yi Ji, Xiuli Zhang, Changxi Zhang, Qi Sun, Chenyang Li, Hong Zhu, Defeng Pan","doi":"10.1007/s10067-025-07479-9","DOIUrl":"10.1007/s10067-025-07479-9","url":null,"abstract":"<p><strong>Background: </strong>Clinical and epidemiological studies suggest a notably higher incidence of atherosclerosis (AS) in systemic sclerosis (SSc) patients, yet their shared molecular mechanisms remain unclear. Therefore, this research was designed to investigate the shared pathogenic mechanisms underlying both SSc and AS.</p><p><strong>Methods: </strong>SSc and AS datasets were acquired from the Gene Expression Omnibus (GEO) database to identify common differentially expressed genes (DEGs). Subsequently, enrichment analyses, protein-protein interaction (PPI) network analysis, coexpression analysis, and TF-mRNA-miRNA regulatory network construction were performed on these common DEGs. Finally, the hub genes were validated using external datasets. Additionally, immune cell infiltration in both SSc and AS was analyzed via the CIBERSORT algorithm, and the relationships between hub genes and immune cell infiltration were assessed.</p><p><strong>Results: </strong>A total of 104 DEGs were identified, with 99 upregulated and 5 downregulated genes. Functional enrichment analysis indicated that the pathogenic mechanisms of these genes are related to immune processes. Through comprehensive bioinformatics analysis, three hub genes (ITGB2, CD163, and CCR5) were identified. Comparative analysis revealed marked upregulation of these genes in pathological specimens relative to controls, highlighting their diagnostic biomarker potential. Furthermore, immune profiling demonstrated macrophage and T lymphocyte predominance in disease microenvironments, implicating these immune populations in SSc and AS pathogenesis.</p><p><strong>Conclusion: </strong>Our study revealed common biomarkers and immune-related pathways that may contribute to the pathogenesis of both SSc and AS. These findings suggest potential immunological mechanisms underlying the development of AS in patients with SSc, providing new insights into the pathological links between these two diseases. Key Points • ITGB2, CD163, and CCR5 may be new diagnostic biomarkers for SSc and AS. • Macrophages and T lymphocytes as key mediators in SSc and AS pathogenesis.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":"3217-3233"},"PeriodicalIF":2.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144332568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical variables and lung ultrasonography for the screening of interstitial lung disease in patients with rheumatoid arthritis.","authors":"Schneeberger Emilce Edith, Perandones Miguel, Rosemffet Marcos Gabriel, Otaola María, Cazenave Tomás, Barbich Tatiana, Carrizo Abarza Virginia, Balcazar Jonathan, Citera Gustavo","doi":"10.1007/s10067-025-07510-z","DOIUrl":"10.1007/s10067-025-07510-z","url":null,"abstract":"<p><p>The best screening way to detect interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) is still debated.</p><p><strong>Objectives: </strong>To evaluate the performance of scores to identify patients with ILD in patients with RA.</p><p><strong>Methods: </strong>Cross-sectional study, adult outpatients with RA were included and those with any disease that can affect lung ultrasonography (LUS) evaluation were excluded. Sociodemographic, clinical, and therapeutic variables were recorded. All patients underwent chest x-rays, pulmonary function tests (PFT), LUS, and high-resolution chest tomography (HRCT). Univariate and multivariate analyses and ROC curves.</p><p><strong>Results: </strong>107 patients with RA, median age of 62 years (IQR 36-84), 82.2% female, and median disease duration 14 years (IQR 1-42). A total of 30 patients (29.5%) had ILD by HRCT. The classic cutoff value of ≥ 5 B lines in the LUS (ILD by HRCT as the gold standard) showed an AUC of 0.86 (95% CI 0.78-0.94), Se 87.1%, and Sp 74.3% for the detection of ILD. A clinical score made up of 5 variables to identify the presence of ILD, based on the strength of association in the multivariate analysis: male sex, crackles, age ≥ 60 years, RF + , anti-CCP + . Range 0-11, cutoff value ≥ 5.5, AUC 0.80 (95% CI 0.70-0.89), Se 75%, and Sp 71%. When we added the LUS variable to this score: lines B ≥ 5, the range was 0-15, a cutoff value ≥ 7.5, AUC 0.88 (95% CI 0.81-0.94), Se improved to 84.4%, and Sp 75%. However, this last score did not exceed the performance of isolated LUS.</p><p><strong>Conclusions: </strong>LUS is a good tool for detecting ILD in patients with RA. Key Points • Interstitial lung disease (ILD) is an extra-musculoskeletal manifestation with high morbidity and mortality in patients with rheumatoid arthritis (RA). Early detection could improve the prognosis of these patients. • High-resolution chest tomography (HRCT) is the gold standard for ILD diagnosis, but high radiation and limited access hinder its use. • Lung ultrasound (LUS) is an excellent tool for detecting ILD in RA patients and performs better than clinical scores. • LUS provides a method of screening for ILD in patients with RA in a simple, cheap, safe, and effective way.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":"3167-3175"},"PeriodicalIF":2.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kikuchi-Fujimoto in the light of the COVID-19: infection and vaccination. A systematic review.","authors":"Nelson Luis Cahuapaza-Gutierrez, Cielo Cinthya Calderon-Hernandez, Tatiana Vanessa Villavicencio-Escudero","doi":"10.1007/s10067-025-07548-z","DOIUrl":"10.1007/s10067-025-07548-z","url":null,"abstract":"<p><strong>Background: </strong>The association between SARS-CoV-2 infection, COVID-19 vaccination, and the development of autoimmune diseases such as the Kikuchi-Fujimoto disease (KFD) is currently unknown.</p><p><strong>Aims: </strong>This study aims to review, synthesize, and analyze the current available evidence on the occurrence of KFD associated with both SARS-CoV-2 infection and COVID-19 vaccination.</p><p><strong>Methods: </strong>Case report, case series, and observational studies were included. Narrative review studies, systematic reviews, meta-analyses, etc., were excluded. A selective bibliographic search was performed in the following databases: PubMed, Scopus, EMBASE, and Web of Science until January 26, 2025. The Joanna Briggs Institute (JBI) tool was used to assess the risk of bias and quality of the studies. The SPSS Statistics tool (version 25.0; IBM Corp., Armonk, N. Y., USA) was used for statistical analysis.</p><p><strong>Results: </strong>A total of 52 patients were reported in the included studies. Of these, 16 developed new-onset KFD as a complication of SARS-CoV-2 infection, while 36 presented with the disease as an adverse effect of COVID-19 vaccination. Cases associated with infection had a mean age of 27.25 ± 16.87 years, and the most frequent clinical manifestations were fever, fatigue, cough, and weight loss. On the other hand, cases related to vaccination had a mean age of 30.8 ± 12.63 years, with a greater association to mRNA technology vaccines, particularly Pfizer-BioNTech (75%) and Moderna (11.1%). Most cases were related to the administration of the first dose (75%). There was a predominance of female sex and the presence of cervical lymphadenopathy in both groups. There were no cases of mortality or unfavorable evolution; on the contrary, almost all patients evolved favorably after timely diagnosis and adequate treatment.</p><p><strong>Conclusions: </strong>SARS-CoV-2 infection could represent a new causative agent of KF disease. However, its occurrence as an adverse effect of COVID-19 vaccination is rare and infrequent, which may be attributed to limited case reporting and the relative novelty of the disease.</p><p><strong>Systematic review registration: </strong>PROSPERO CRD42024522470.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":"3153-3166"},"PeriodicalIF":2.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the editor: Reflections on idiopathic granulomatous mastitis.","authors":"Pin Wang","doi":"10.1007/s10067-025-07547-0","DOIUrl":"10.1007/s10067-025-07547-0","url":null,"abstract":"","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":"3381-3382"},"PeriodicalIF":2.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144474121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rehospitalization to evaluate outcomes during clinical courses in patients with elderly-onset idiopathic inflammatory myositis: a retrospective single-center study.","authors":"Jun-Ichi Kurashina, Yasuhiro Shimojima, Dai Kishida, Takanori Ichikawa, Yoshiki Sekijima","doi":"10.1007/s10067-025-07540-7","DOIUrl":"10.1007/s10067-025-07540-7","url":null,"abstract":"<p><strong>Objectives: </strong>The features of rehospitalization, associated with the long-term clinical outcome, remain uncertain in idiopathic inflammatory myositis (IIM). We evaluated the frequency and causes of rehospitalization in patients with elderly (≥ 65 years)-onset IIM, EOM compared to those with young (< 65 years)-onset IIM (YOM).</p><p><strong>Method: </strong>Electronic medical records of patients with IIM were reviewed over 6 years. Rehospitalization was defined as first admission during outpatient care following successful induction and maintenance of IIM treatment. Opportunities, causes, and relevant factors for hospitalization were obtained for patients with EOM and those with YOM.</p><p><strong>Results: </strong>There were 108 patients identified: 34 with EOM (median age, 71 years; 22 women) and 74 with YOM (median age, 49 years; 52 women). Rehospitalization was significantly higher in patients with EOM (n = 25, 73.5%) compared to those with YOM (n = 36, 48.6%) during a 2-year observation period (p < 0.05). In the rehospitalized patients with EOM, there was a significantly lower deterioration in disease activity (n = 8; p < 0.05) but higher incidence of infections present (n = 5; p < 0.05) compared to those with YOM. The Cox proportional hazards model indicated a significant association between increased age and rehospitalization (hazard ratio, 1.024; 95% confidence interval, 1006‒1.042; p < 0.05).</p><p><strong>Conclusions: </strong>Patients with EOM were more likely to experience rehospitalization, and infections were identified more significantly compared to those with YOM. These findings may be useful for managing the long-term clinical outcome in IIM. Key Points • Patients with elderly-onset idiopathic inflammatory myositis (IIM) are more likely to be rehospitalized than those with young-onset IIM. • Among patients who experienced rehospitalization, those with elderly-onset IIM had a significantly higher rate of remission than those with young-onset IIM. • As a cause of rehospitalization, infections were significantly more common in patients with elderly-onset IIM than in those with young-onset IIM.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":"3245-3251"},"PeriodicalIF":2.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}